Orange Book Blog

At the intersection of Patent and FDA Law

OBB News Briefs

Prof. Chris Holman, who has contributed to this blog in the past, recently started his own blog: Holman’s Biotech IP Blog. Formerly in-house counsel at a biotech company, Chris offers valuable insights on biotech IP law.
“Big Pharma Faces Grim Prognosis” was the top story on the front page of the Wall Street Journal Thursday. It proclaims: “Over the next few years, the pharmaceutical business will hit a wall.” Summaries of the article appear on the WSJ Health Blog and Pharmalot.
Watson Pharmaceuticals announced Thursday that it settled patent litigation with Novartis concerning its generic version of Novartis’s Exelon.
Sun Pharma also announced a settlement with Novartis on Thursday, concerning its own generic version of Exelon. On October 23, Sun announced that the FDA granted final approval to its ANDA for generic Exelon.
On Tuesday, Watson announced that it settled litigation with Biovail over its generic version of Cardizem LA. Biovail also put out its own press release.
King Pharmaceuticals announced Monday that the Federal Circuit denied its petition for rehearing and rehearing en banc of the Federal Circuit’s September 11 decision invalidating the patent on Altace.